announced today that its CEO and Founder, James R. Baker, Jr., M.D., will present
new data from studies of its nanoemulsion-based adjuvant platform during the
World Influenza Congress, taking place from December 7-9, 2009 in Brussels,
Belgium. The presentation details are as follows:
Dr. Baker will discuss the mechanisms of action and key characteristics of
intranasal nanoemulsion-adjuvanted vaccines, and will share additional data
- The nanoemulsion adjuvant's uptake into dendritic cells and generation
of Th1-biased immunity without inducing an inflammatory response;
- The efficacy of nanoemulsion-adjuvanted intranasal influenza vaccines in
- The efficacy of nanoemulsion-based adjuvants in subcutaneous and intramuscular
- The safety results from NanoBio's ongoing Phase 1 clinical study
of NB-1008, a nanoemulsion-adjuvanted seasonal influenza vaccine administered
by nasal dropper.
Oral Presentation: Triggering Robust Immune Responses through Nanoemulsion-based
Intranasal Vaccine Adjuvants
Date: Wednesday, December 9 at 10:05 a.m.
Location: Hilton Brussels Hotel, Belgium
Dr. Baker will also be a featured speaker in a panel session titled, "How
can we develop strategies to maximize chances of approval for novel adjuvants?"
on Wednesday, Dec. 9 at 11:30 a.m.
NanoBio's nanoemulsion-based, intranasal vaccines have elicited robust
immune responses in animals vaccinated against seasonal and pandemic influenza,
hepatitis B, RSV, HIV, pneumococcal, anthrax, smallpox and other diseases. The
company's NanoStat adjuvant platform technology has demonstrated
numerous potential advantages over traditional vaccines, including: the ability
to generate robust mucosal, systemic and cellular immunity; antigen-sparing
qualities; cross-protection against non-vaccinated strains; ability to adjuvant
multiple antigen types without inducing inflammation; thermally stabilizing
the vaccine; and removing the need for needles.
NanoBio Corporation is a privately held biopharmaceutical company focused
on developing and commercializing dermatological products, anti-infective treatments
and intranasal vaccines derived from its patented NanoStat technology
platform. The company's lead dermatology and anti-infective product candidates
include treatments for herpes labialis (cold sores), onychomycosis (nail fungus),
tinea capitis, acne, molluscum contagiosum, and cystic fibrosis. The company's
headquarters and laboratory facilities are located in Ann Arbor, Michigan. NanoBio
is a spin-off from the University of Michigan and holds the exclusive global
license to the nanoemulsion platform technology.